Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Enzyme replacement therapy 3600 synopsis, 2018 – 2032 (USD Million)
2.1.1 Business trends
2.1.2 Region trends
2.1.3 Enzyme type trends
2.1.4 Indication trends
2.1.5 Route of Administration trends
2.1.6 End-user trends
Chapter 3 Enzyme Replacement Therapy Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Million)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of rare genetic disorders
3.2.1.2 Rising demand for effective treatment options
3.2.1.3 Growing awareness of rare genetic diseases
3.2.1.4 Advancements in biotechnology and genetic engineering
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of therapy
3.2.2.2 Limited availability of ERT products
3.3 Growth potential analysis
3.3.1 By enzyme type
3.3.2 By indication
3.3.3 By route of administration
3.3.4 By end-user
3.3.5 By region
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Technology landscape
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Enzyme Replacement Therapy Market Estimates and Forecast, By Enzyme Type, 2018-2032 (USD Million)
5.1 Key trends, by enzyme type
5.2 Imiglucerase
5.3 Agalsidase beta
5.4 Taliglucerase
5.5 Velaglucerase alfa
5.6 Laronidase
5.7 Alglucosidase alfa
5.8 Galsulfase
5.9 Idursulfase
5.10 Pancreatic enzymes
5.11 Pegademase
5.12 Other enzyme types
Chapter 6 Enzyme Replacement Therapy Market Estimates and Forecast, By Indication, 2018-2032 (USD Million)
6.1 Key trends, by indication
6.2 Gaucher disease
6.3 Fabry disease
6.4 Pompe disease
6.5 Plasma cell disorders
6.6 SCID
6.7 Mucopolysaccharidosis (MPS)
6.7.1 MPS I - Hurler, Hurler Scheie and Scheie
6.7.2 MPS II - Hunter
6.7.3 MPS III - Sanfilippo
6.7.4 Other mucopolysaccharidosis
6.8 Other indications
Chapter 7 Enzyme Replacement Therapy Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Million)
7.1 Key trends, by route of administration
7.2 Parenteral
7.3 Oral
Chapter 8 Enzyme Replacement Therapy Market Estimates and Forecast, By End-user, 2018-2032 (USD Million)
8.1 Key trends, by end-user
8.2 Hospitals
8.3 Infusion centers
8.4 Other end-users
Chapter 9 Enzyme Replacement Therapy Market Estimates and Forecast, By Region, 2018-2032 (USD Million)
9.1 Key trends, by region
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East & Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 Rest of Middle East & Africa
Chapter 10 Company Profiles
10.1 Sanofi
10.2 Biomarin Pharmaceutical Inc.
10.3 AbbVie Inc.
10.4 Pfizer, Inc.
10.5 Alexion Pharmaceuticals Inc.
10.6 Allergan plc
10.7 Horizon Pharma Public Limited Company
10.8 Recordati Rare Diseases
10.9 Protalix Biotherapeutics
10.10 Amicus Therapeutics, Inc.
